Malignant Neoplastic Disease clinical trials at UC Cancer
2 research studies open to eligible people
Showing trials for
Phase 1/2 Study in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL 2
open to eligible people ages 18 years and up
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
at UC Irvine UCLA
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
open to eligible people ages 18 years and up
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
at UC Irvine UCSD
Last updated: